MEDP - Medpace Holdings Inc Stock Price, Fair Value and News

381.93USD+1.43 (+0.38%)Market Closed

Market Summary

USD381.93+1.43

Market Closed

0.38%

MEDP Alerts

Big jump in Earnings (Y/Y)

MEDP Stock Price

View Fullscreen

MEDP RSI Chart

MEDP Valuation

Market Cap

11.8B

Price/Earnings (Trailing)

34.85

Price/Sales (Trailing)

5.83

EV/EBITDA

26.81

Price/Free Cashflow

23.55

MEDP Price/Sales (Trailing)

MEDP Profitability

EBT Margin

19.56%

Return on Equity

44.5%

Return on Assets

17.7%

Free Cashflow Yield

4.25%

MEDP Fundamentals

MEDP Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

14.59%

Rev. Growth (Qtr)

3.34%

MEDP Earnings

Earnings (TTM)

339.8M

Earnings Growth (Yr)

44.68%

Earnings Growth (Qtr)

-13.88%

Breaking Down MEDP Revenue

Last 7 days

-9.3%

Last 30 days

-5.8%

Last 90 days

-3.5%

Trailing 12 Months

53.5%

How does MEDP drawdown profile look like?

MEDP Financial Health

Current Ratio

0.88

MEDP Investor Care

Shares Dilution (1Y)

1.44%

Diluted EPS (TTM)

10.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0B	2.0B	0	0
2023	1.6B	1.7B	1.8B	1.9B
2022	1.2B	1.3B	1.4B	1.5B
2021	955.0M	1.0B	1.1B	1.1B
2020	891.1M	882.0M	896.1M	925.9M
2019	742.3M	786.2M	823.2M	861.0M
2018	492.6M	556.5M	625.2M	704.6M
2017	428.6M	428.9M	431.7M	436.2M
2016	374.7M	390.3M	406.0M	421.6M
2015	0	0	0	359.1M
2014	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

CEO	Dr. August James Troendle M.D.
WEBSITE	medpace.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	5600

Medpace Holdings Inc Frequently Asked Questions

What is the ticker symbol for Medpace Holdings Inc? What does MEDP stand for in stocks?

MEDP is the stock ticker symbol of Medpace Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Medpace Holdings Inc (MEDP)?

As of Fri Jul 26 2024, market cap of Medpace Holdings Inc is 11.84 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEDP stock?

You can check MEDP's fair value in chart for subscribers.

Is Medpace Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MEDP is over valued or under valued. Whether Medpace Holdings Inc is cheap or expensive depends on the assumptions which impact Medpace Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEDP.

What is Medpace Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, MEDP's PE ratio (Price to Earnings) is 34.85 and Price to Sales (PS) ratio is 5.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEDP PE ratio will change depending on the future growth rate expectations of investors.